Magenta Therapeutics exercises ATAC licence option
Magenta Therapeutics has exercised the option to licence Heidelberg Pharma AGs anti-CD45-Antibody Targeted Amanitin Conjugate (ATAC).
SciRhom targets autoimmunity switch
Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.
AMR: ENABLE selects Mutabilis candidate
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).
NSCLC: Bemcentinib + anti-PD1 triple PFS
Bergen Bio ASAs Axl kinase blocker bemcentinib in combination with MSDs pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).
Transposase makes CAR-T production cheaper
German researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies.
Test detects breast cancer in earliest stage
Sherlock Bioscience and Mologic enter partnership
Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings.
Protein protects against liver fibrosis
German researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver.
bit bio restarts with new management
Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
Researchers identify viral inflammation switch
A team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.